Revenue Downgrade: Here's What Analysts Forecast For Coherus BioSciences, Inc. (NASDAQ:CHRS)
Revenue Downgrade: Here's What Analysts Forecast For Coherus BioSciences, Inc. (NASDAQ:CHRS)
One thing we could say about the analysts on Coherus BioSciences, Inc. (NASDAQ:CHRS) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. There was a fairly draconian cut to their revenue estimates, perhaps an implicit admission that previous forecasts were much too optimistic.
關於Coherus BioSciences, Inc.(納斯達克股票代碼:CHRS)的分析師,我們可以說的一件事——他們並不樂觀,他們剛剛對該組織的短期(法定)預測進行了重大負面修正。他們對收入的估計進行了相當嚴厲的削減,這可能意味着他們承認先前的預測過於樂觀。
Following the downgrade, the current consensus from Coherus BioSciences' eight analysts is for revenues of US$339m in 2024 which - if met - would reflect a substantial 61% increase on its sales over the past 12 months. Prior to the latest estimates, the analysts were forecasting revenues of US$434m in 2024. The consensus view seems to have become more pessimistic on Coherus BioSciences, noting the sizeable cut to revenue estimates in this update.
降級之後,Coherus BioSciences的八位分析師目前的共識是,2024年的收入爲3.39億美元,如果達到,這將反映出其在過去12個月中銷售額大幅增長61%。在最新估計之前,分析師預測2024年的收入爲4.34億美元。Coherus BioSciences的共識觀點似乎變得更加悲觀,他們指出,本次更新大幅削減了收入預期。
See our latest analysis for Coherus BioSciences
查看我們對 Coherus BioSciences 的最新分析
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240131/0-b0d4e86d50e9c5ebd4e181917a33fbdc-0-24631661588c95d849d0301bbe2aa400.png/big)
Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. It's clear from the latest estimates that Coherus BioSciences' rate of growth is expected to accelerate meaningfully, with the forecast 46% annualised revenue growth to the end of 2024 noticeably faster than its historical growth of 7.3% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 16% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Coherus BioSciences to grow faster than the wider industry.
我們可以從大局的角度看待這些估計值的另一種方式,例如預測如何與過去的表現相提並論,以及預測相對於業內其他公司是否或多或少看漲。從最新估計中可以明顯看出,Coherus BioSciences的增長率預計將大幅加速,預計到2024年底的年化收入增長爲46%,將明顯快於其過去五年中每年7.3%的歷史增長。相比之下,我們的數據表明,預計類似行業的其他公司(有分析師報道)的收入將以每年16%的速度增長。顯而易見,儘管增長前景比最近更加光明,但分析師也預計Coherus BioSciences的增長速度將超過整個行業。
The Bottom Line
底線
The most important thing to take away is that analysts cut their revenue estimates for next year. They're also forecasting more rapid revenue growth than the wider market. Overall, given the drastic downgrade to next year's forecasts, we'd be feeling a little more wary of Coherus BioSciences going forwards.
要了解的最重要的一點是,分析師下調了明年的收入預期。他們還預測收入增長將比整個市場更快。總體而言,鑑於明年的預測大幅下調,我們將對Coherus BioSciences的未來更加警惕。
That said, the analysts might have good reason to be negative on Coherus BioSciences, given dilutive stock issuance over the past year. Learn more, and discover the 2 other risks we've identified, for free on our platform here.
儘管如此,鑑於過去一年的股票發行量呈稀釋態度,分析師可能有充分的理由對Coherus BioSciences持負面看法。在此處的平台上免費了解更多,並發現我們已確定的其他 2 種風險。
Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.
尋找可能達到轉折點的有趣公司的另一種方法是使用內部人士收購的成長型公司的免費清單,跟蹤管理層是買入還是賣出。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。